RA
PRVA icon

Royce & Associates’s Privia Health PRVA Stock Holding History

Royce & Associates’s Portfolio PRVA Stock Details PRVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2M Buy
825,171
+157,530
+24% +$3.65M 0.17% 198
2026
Q1 		$13.7M Buy
667,641
+72,000
+12% +$1.62M 0.14% 246
2025
Q4 		$14.1M Sell
595,641
-11,550
-2% -$281K 0.14% 216
2025
Q3 		$15.1M Buy
607,191
+214,166
+54% +$4.61M 0.15% 209
2025
Q2 		$9.04M Buy
393,025
+89,350
+29% +$2.07M 0.09% 315
2025
Q1 		$6.82M Buy
+303,675
New +$7.06M 0.07% 385
2024
Q3 		– Sell
-292,400
Closed -$5.08M – 895
2024
Q2 		$5.08M Hold
292,400
– – 0.05% 478
2024
Q1 		$5.73M Sell
292,400
-64,000
-18% -$1.35M 0.05% 464
2023
Q4 		$8.21M Sell
356,400
-78,000
-18% -$1.75M 0.08% 369
2023
Q3 		$9.99M Buy
434,400
+33,000
+8% +$839K 0.1% 283
2023
Q2 		$10.5M Buy
401,400
+304,400
+314% +$8.04M 0.1% 300
2023
Q1 		$2.68M Buy
97,000
+20,000
+26% +$528K 0.03% 618
2022
Q4 		$1.75M Buy
+77,000
New +$2.14M 0.02% 668

Other funds holding PRVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Royce & Associates's PRVA Position: Q2 2026 in Review

Royce & Associates increased its Privia Health (PRVA) stake by 24% in Q2 2026, buying an estimated $3.65M and bringing the position to 825,171 shares worth $21.2M. The position accounts for 0.17% of the portfolio, ranked #198.

Royce & Associates first reported a position in PRVA in Q4 2022 and has held it in 13 quarters since. 301 funds tracked by Wall St. Rank hold PRVA as of Q2 2026.

  • Royce & Associates held 825,171 shares of Privia Health worth $21.2M as of Q2 2026.
  • Royce & Associates bought 157,530 Privia Health shares in Q2 2026, an estimated $3.65M.
  • Privia Health made up 0.17% of Royce & Associates's portfolio in Q2 2026, its #198 holding.
  • Royce & Associates first reported a position in Privia Health in Q4 2022 and has held it in 13 quarters since.
  • 301 funds tracked by Wall St. Rank held Privia Health as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.